COMMUNIQUÉS West-GlobeNewswire

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
03/03/2026
GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings [...]
Cirrus Therapeutics Announces Strategic Expansion to Singapore and Other Key Updates Supporting its Growth as a Leading Global Ocular Immunology Company
03/03/2026
Expands global footprint to Singapore, gaining access to Asia-Pacific region to support research, clinical development and partnering activities Forms strategic partnership with A*STAR to accelerate advancement of [...]
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH)
03/03/2026
Approval expands indication of JUXTAPID ® to include children 2 years of age and older with HoFH This announcement was made during the week of Rare Disease Day, which aims to raise awareness about the impact of rare [...]
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
03/03/2026
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
03/03/2026
Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health Sufficient clinical samples collected to support statistical analysis and FDA submission Company [...]
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
03/03/2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
03/03/2026
Echocardiography outcomes show treated patients having reduced negative remodeling of heart volumes SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell- [...]
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
03/03/2026
CNP-104 improved key cholestasis endpoints at one year, including a composite serum alkaline phosphatase (ALP) and bilirubin biochemical response Durable effects observed across liver stiffness, prognostic risk markers [...]
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026
- CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited ( [...]
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests [...]
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs CAMBRIDGE, Mass [...]
SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments
03/03/2026
March 3, 2026 With a total budget of EUR 21.5 million, the four-year SHERPA research project is coordinated by Philips and co-funded by the EU Innovative Health Initiative (IHI) and industry partners The project focuses [...]
Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval
03/03/2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients with Rheumatoid [...]
Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study
03/03/2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today shared interim top- [...]
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03/03/2026
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead [...]
Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases
03/03/2026
Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated statistically [...]
SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet Microbe
03/03/2026
First-ever randomized, placebo-controlled Phase 1 trial - published in The Lancet Microbe - supports SNIPR001’s safety, tolerability, and restriction to the gastrointestinal tract in healthy participants Oral SNIPR001 [...]

Pages